For both promoters and enhancers we also identified a subset of disruptive variants that target response elements for factors of special interest to prostate cancer, namely AR, FOXA1, NKX3-1, TCF7L2, MYC, GATA1 and GATA3. This evidence concerns the gene TCF7L2 and prostate carcinoma.